A detailed history of Argus Investors' Counsel, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Argus Investors' Counsel, Inc. holds 1,359 shares of ABBV stock, worth $227,292. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,359
Holding current value
$227,292
% of portfolio
0.15%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

BUY
$159.82 - $182.1 $217,195 - $247,473
1,359 New
1,359 $247,000
Q1 2019

Apr 16, 2019

SELL
$77.14 - $90.79 $385,237 - $453,405
-4,994 Closed
0 $0
Q4 2018

Feb 06, 2019

BUY
$77.85 - $96.01 $56,207 - $69,319
722 Added 16.9%
4,994 $460,000
Q3 2018

Oct 16, 2018

BUY
$88.91 - $98.84 $54,768 - $60,885
616 Added 16.85%
4,272 $0
Q2 2018

Jul 19, 2018

BUY
$89.78 - $106.23 $328,235 - $388,376
3,656 New
3,656 $339,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $296B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Argus Investors' Counsel, Inc. Portfolio

Follow Argus Investors' Counsel, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Argus Investors' Counsel, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Argus Investors' Counsel, Inc. with notifications on news.